



PRODUCT: **QINLOCK®**

COMPANY: Deciphera Pharmaceuticals

THERAPEUTIC AREA & INDICATION:
Treatment of gastrointestinal stromal tumor

ABOUT THE PRODUCT

QINLOCK®, a novel switch control tyrosine kinase inhibitor, was specifically designed to broadly inhibit KIT and PDGFRA mutated kinases with a unique dual mechanism of action. QINLOCK binds to both the switch pocket region and the activation switch securing the target kinase into an inactive conformation, resulting in the inhibition of downstream signaling and cell proliferation.

In INVICTUS, QINLOCK provided a powerful PFS benefit and reduced the risk of progression or death by 85% in patients with ≥4th-line advanced GIST. Patients received a clinically meaningful survival benefit when treated with QINLOCK versus placebo (median OS – 15.1 months versus 6.6 months).